[177Lu]-PSMA-617 Has Activity in Castration-Resistant Prostate Cancer [Clinical Trials]

Radionuclide treatment with [¹⁷⁷Lu]-PSMA-617 (LuPSMA) reduced PSA levels by ≥50% in 57% of patients.

https://ift.tt/2KDwv3j